Details of the Drug

General Information of Drug (ID: DMTW6IU)

Drug Name
Methadone
Synonyms
Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone
Indication
Disease Entry ICD 11 Status REF
Dry cough MD12 Approved [1]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 309.4
Topological Polar Surface Area (xlogp) 3.9
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-7.5 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 36-100% [2]
Clearance
The clearance of drug is 5.9C13 L/h [4]
Elimination
24% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 15C207 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.61574 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.21% [6]
Vd
The volume of distribution (Vd) of drug is 189-470 L [4]
Water Solubility
The ability of drug to dissolve in water is measured as 120 mg/mL [3]
Chemical Identifiers
Formula
C21H27NO
IUPAC Name
6-(dimethylamino)-4,4-diphenylheptan-3-one
Canonical SMILES
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
InChIKey
USSIQXCVUWKGNF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4095
ChEBI ID
CHEBI:6807
CAS Number
76-99-3
DrugBank ID
DB00333
TTD ID
D09OJQ
VARIDT ID
DR00141
INTEDE ID
DR1039
ACDINA ID
D00406

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Agonist [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [10]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [11]
Aromatase (CYP19A1) DEQX145 CP19A_HUMAN Substrate [12]
Cytochrome P450 2B6 (CYP2B6)
Main DME 		DEPKLMQ CP2B6_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [10]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [10]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Methadone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Dextromethorphan DMUDJZM Moderate Additive CNS depression effects by the combination of Methadone and Dextromethorphan. Cough [MD12] [100]
Coadministration of a Drug Treating the Disease Different from Methadone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Methadone and Methylene blue. Acquired methaemoglobinaemia [3A93] [101]
Metreleptin DM1NOEK Moderate Increased metabolism of Methadone caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [102]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Methadone and Ivosidenib. Acute myeloid leukaemia [2A60] [103]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Methadone and Midostaurin. Acute myeloid leukaemia [2A60] [104]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Methadone and Idarubicin. Acute myeloid leukaemia [2A60] [104]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Methadone and Daunorubicin. Acute myeloid leukaemia [2A60] [104]
Arn-509 DMT81LZ Major Increased metabolism of Methadone caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [102]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Methadone and Gilteritinib. Acute myeloid leukaemia [2A60] [104]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Methadone and Oliceridine. Acute pain [MG31] [105]
Chlorzoxazone DMCYVDT Major Additive CNS depression effects by the combination of Methadone and Chlorzoxazone. Acute pain [MG31] [106]
Emapalumab DMZG5WL Moderate Altered metabolism of Methadone due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [107]
Scopolamine DMOM8AL Moderate Additive CNS depression effects by the combination of Methadone and Scopolamine. Addictive disorder [6C50-6C5Z] [108]
Mitotane DMU1GX0 Major Increased metabolism of Methadone caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [102]
Terfenadine DM4KLPT Major Increased risk of prolong QT interval by the combination of Methadone and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [104]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Tacrine. Alzheimer disease [8A20] [104]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Galantamine. Alzheimer disease [8A20] [104]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Rivastigmine. Alzheimer disease [8A20] [104]
Donepezil DMIYG7Z Minor Decreased metabolism of Methadone caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [109]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Methadone and Metronidazole. Amoebiasis [1A36] [110]
Siltuximab DMGEATB Moderate Altered metabolism of Methadone due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [107]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Methadone and Ivabradine. Angina pectoris [BA40] [107]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Methadone and Bepridil. Angina pectoris [BA40] [104]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Methadone and Dronedarone. Angina pectoris [BA40] [104]
Nifedipine DMSVOZT Moderate Decreased metabolism of Methadone caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [111]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Methadone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [112]
Buspirone DMBS632 Major Additive CNS depression effects by the combination of Methadone and Buspirone. Anxiety disorder [6B00-6B0Z] [106]
Clorazepate DMC3JST Major Additive CNS depression effects by the combination of Methadone and Clorazepate. Anxiety disorder [6B00-6B0Z] [113]
Alprazolam DMC7XDN Major Additive CNS depression effects by the combination of Methadone and Alprazolam. Anxiety disorder [6B00-6B0Z] [106]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Methadone and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [114]
Hydroxyzine DMF8Y74 Major Additive CNS depression effects by the combination of Methadone and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [106]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Methadone and Halazepam. Anxiety disorder [6B00-6B0Z] [106]
Chlordiazepoxide DMTN5XI Major Additive CNS depression effects by the combination of Methadone and Chlordiazepoxide. Anxiety disorder [6B00-6B0Z] [106]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Methadone and Chlormezanone. Anxiety disorder [6B00-6B0Z] [106]
Clobazam - Lundbeck DMW1OQ0 Major Additive CNS depression effects by the combination of Methadone and Clobazam - Lundbeck. Anxiety disorder [6B00-6B0Z] [106]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Methadone and Oxazepam. Anxiety disorder [6B00-6B0Z] [106]
Promazine DMZAL7W Major Increased risk of prolong QT interval by the combination of Methadone and Promazine. Appearance/behaviour symptom [MB23] [104]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Methadone and Cilostazol. Arterial occlusive disease [BD40] [104]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Methadone and Voriconazole. Aspergillosis [1F20] [104]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Methadone and Posaconazole. Aspergillosis [1F20] [104]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Levalbuterol. Asthma [CA23] [115]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Methadone and Terbutaline. Asthma [CA23] [116]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Pirbuterol. Asthma [CA23] [116]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Methadone and Salbutamol. Asthma [CA23] [117]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Formoterol. Asthma [CA23] [116]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Methadone and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [104]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Methadone and Desipramine. Attention deficit hyperactivity disorder [6A05] [104]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Methadone and Ofloxacin. Bacterial infection [1A00-1C4Z] [104]
Oritavancin DM28D05 Moderate Increased metabolism of Methadone caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [102]
Ciprofloxacin XR DM2NLS9 Major Decreased metabolism of Methadone caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [118]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Methadone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [118]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Methadone and Clarithromycin. Bacterial infection [1A00-1C4Z] [104]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Methadone and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [104]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Methadone and Sparfloxacin. Bacterial infection [1A00-1C4Z] [119]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Methadone caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [111]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Methadone and Gemifloxacin. Bacterial infection [1A00-1C4Z] [104]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Methadone and Norfloxacin. Bacterial infection [1A00-1C4Z] [104]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Methadone and Levofloxacin. Bacterial infection [1A00-1C4Z] [104]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Methadone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [111]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Methadone and Lomefloxacin. Bacterial infection [1A00-1C4Z] [104]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Methadone and Retigabine. Behcet disease [4A62] [104]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Methadone and Cariprazine. Bipolar disorder [6A60] [106]
Pexidartinib DMS2J0Z Major Increased metabolism of Methadone caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [102]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Methadone and Loperamide. Bowel habit change [ME05] [107]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Methadone and Eribulin. Breast cancer [2C60-2C6Y] [104]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Methadone and Lapatinib. Breast cancer [2C60-2C6Y] [104]
Tucatinib DMBESUA Moderate Decreased metabolism of Methadone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [111]
Alpelisib DMEXMYK Moderate Increased metabolism of Methadone caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [120]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Methadone and Tamoxifen. Breast cancer [2C60-2C6Y] [104]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Methadone and Toremifene. Breast cancer [2C60-2C6Y] [104]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Methadone and Bosutinib. Breast cancer [2C60-2C6Y] [104]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Methadone and Grepafloxacin. Bronchitis [CA20] [119]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Methadone and Sotalol. Cardiac arrhythmia [BC9Z] [104]
Secobarbital DM14RF5 Major Additive CNS depression effects by the combination of Methadone and Secobarbital. Chronic insomnia [7A00] [111]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Methadone and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [104]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Olodaterol. Chronic obstructive pulmonary disease [CA22] [116]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [115]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Methadone and Salmeterol. Chronic obstructive pulmonary disease [CA22] [116]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [116]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Methadone and Arformoterol. Chronic obstructive pulmonary disease [CA22] [116]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Methadone caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [102]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Methadone and Dihydrocodeine. Chronic pain [MG30] [113]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Methadone and Levomilnacipran. Chronic pain [MG30] [100]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Methadone and Oxaliplatin. Colorectal cancer [2B91] [104]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Methadone and Isoproterenol. Conduction disorder [BC63] [116]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Methadone and Olopatadine. Conjunctiva disorder [9A60] [121]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Methadone and Halothane. Corneal disease [9A76-9A78] [104]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Methadone and Propofol. Corneal disease [9A76-9A78] [122]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Methadone and Sevoflurane. Corneal disease [9A76-9A78] [104]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Methadone and Probucol. Coronary atherosclerosis [BA80] [104]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Methadone and Clofazimine. Crohn disease [DD70] [104]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Methadone and Mifepristone. Cushing syndrome [5A70] [104]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Methadone and Pasireotide. Cushing syndrome [5A70] [104]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Methadone and Osilodrostat. Cushing syndrome [5A70] [104]
Aminoglutethimide DMWFHMZ Major Increased metabolism of Methadone caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [102]
Lumacaftor DMCLWDJ Major Increased metabolism of Methadone caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [123]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Methadone and Ethanol. Cystitis [GC00] [124]
MK-8228 DMOB58Q Moderate Decreased metabolism of Methadone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [111]
Aprepitant DM053KT Moderate Decreased metabolism of Methadone caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [111]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Methadone and Sertraline. Depression [6A70-6A7Z] [104]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Methadone and Trimipramine. Depression [6A70-6A7Z] [104]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Methadone and Cyclobenzaprine. Depression [6A70-6A7Z] [106]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Methadone and Imipramine. Depression [6A70-6A7Z] [104]
Fluoxetine DM3PD2C Major Decreased metabolism of Methadone caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [125]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Methadone and Nortriptyline. Depression [6A70-6A7Z] [104]
Vilazodone DM4LECQ Moderate Additive serotonergic effects by the combination of Methadone and Vilazodone. Depression [6A70-6A7Z] [100]
Paroxetine DM5PVQE Moderate Additive serotonergic effects by the combination of Methadone and Paroxetine. Depression [6A70-6A7Z] [100]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Methadone and Selegiline. Depression [6A70-6A7Z] [101]
Vortioxetine DM6F1PU Moderate Additive serotonergic effects by the combination of Methadone and Vortioxetine. Depression [6A70-6A7Z] [100]
Duloxetine DM9BI7M Moderate Increased plasma concentrations of Methadone and Duloxetine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [126]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Methadone and Isocarboxazid. Depression [6A70-6A7Z] [101]
Milnacipran DMBFE74 Moderate Additive serotonergic effects by the combination of Methadone and Milnacipran. Depression [6A70-6A7Z] [100]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Methadone and Escitalopram. Depression [6A70-6A7Z] [104]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Methadone and Tranylcypromine. Depression [6A70-6A7Z] [101]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Methadone and Desvenlafaxine. Depression [6A70-6A7Z] [100]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Methadone and OPC-34712. Depression [6A70-6A7Z] [106]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Methadone and Phenelzine. Depression [6A70-6A7Z] [101]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Methadone and Clomipramine. Depression [6A70-6A7Z] [104]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Methadone and Trazodone. Depression [6A70-6A7Z] [104]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Methadone and Amoxapine. Depression [6A70-6A7Z] [104]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Methadone and Mirtazapine. Depression [6A70-6A7Z] [104]
Protriptyline DMNHTZI Major Increased risk of prolong QT interval by the combination of Methadone and Protriptyline. Depression [6A70-6A7Z] [104]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Methadone and Doxepin. Depression [6A70-6A7Z] [127]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Methadone and Maprotiline. Depression [6A70-6A7Z] [104]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Methadone and Esketamine. Depression [6A70-6A7Z] [110]
Griseofulvin DMK54YG Moderate Increased metabolism of Methadone caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [102]
Hyoscyamine DM804UR Moderate Additive CNS depression effects by the combination of Methadone and Hyoscyamine. Digestive system disease [DE2Z] [108]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Methadone and Mepenzolate. Digestive system disease [DE2Z] [108]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive serotonergic effects by the combination of Methadone and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [100]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Methadone and Oxybutynine. Discovery agent [N.A.] [108]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Methadone and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [113]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Methadone and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [104]
Trihexyphenidyl DMB19L8 Moderate Additive CNS depression effects by the combination of Methadone and Trihexyphenidyl. Dystonic disorder [8A02] [128]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Methadone and Deutetrabenazine. Dystonic disorder [8A02] [104]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Methadone and Ingrezza. Dystonic disorder [8A02] [104]
Fenfluramine DM0762O Moderate Additive serotonergic effects by the combination of Methadone and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [100]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Methadone and Diazepam. Epilepsy/seizure [8A61-8A6Z] [106]
Primidone DM0WX6I Major Increased metabolism of Methadone caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [111]
Felbamate DM1V5ZS Moderate Increased metabolism of Methadone caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Oxcarbazepine DM5PU6O Major Increased metabolism of Methadone caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Methadone and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [129]
Cenobamate DMGOVHA Major Increased metabolism of Methadone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Stiripentol DMMSDOY Moderate Decreased metabolism of Methadone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [111]
Fosphenytoin DMOX3LB Major Increased metabolism of Methadone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Methadone and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [106]
Rufinamide DMWE60C Moderate Increased metabolism of Methadone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Phenobarbital DMXZOCG Major Increased metabolism of Methadone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [111]
Carbamazepine DMZOLBI Major Increased metabolism of Methadone caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Eslicarbazepine DMZREFQ Major Increased metabolism of Methadone caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Timolol DM3NXRU Moderate Decreased metabolism of Methadone caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [130]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Methadone and Dantrolene. Fever [MG26] [106]
Tazemetostat DMWP1BH Moderate Increased metabolism of Methadone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [102]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Methadone and Solifenacin. Functional bladder disorder [GC50] [104]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Methadone and Tolterodine. Functional bladder disorder [GC50] [108]
Darifenacin DMWXLYZ Moderate Additive antimotility effects by the combination of Methadone and Darifenacin. Functional bladder disorder [GC50] [131]
Itraconazole DMCR1MV Major Decreased metabolism of Methadone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [110]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Methadone and Pentamidine. Fungal infection [1F29-1F2F] [104]
Miconazole DMPMYE8 Moderate Decreased metabolism of Methadone caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [132]
Ketoconazole DMPZI3Q Major Decreased metabolism of Methadone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [133]
Propantheline DM2EN6G Moderate Additive CNS depression effects by the combination of Methadone and Propantheline. Gastric ulcer [DA60] [108]
Cimetidine DMH61ZB Moderate Decreased metabolism of Methadone caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [111]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Methadone and Cisapride. Gastro-oesophageal reflux disease [DA22] [104]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Methadone and Sunitinib. Gastrointestinal stromal tumour [2B5B] [104]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Methadone and Brimonidine. Glaucoma [9C61] [134]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Methadone caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [102]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Methadone caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [111]
Rifampin DMA8J1G Major Increased metabolism of Methadone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [123]
Rifapentine DMCHV4I Major Increased metabolism of Methadone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [102]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Methadone and Procarbazine. Hodgkin lymphoma [2B30] [101]
Delavirdine DM3NF5G Moderate Decreased metabolism of Methadone caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [111]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Methadone and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [104]
Efavirenz DMC0GSJ Moderate Increased metabolism of Methadone caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Methadone and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [135]
Etravirine DMGV8QU Moderate Increased metabolism of Methadone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [136]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Methadone and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [127]
Rilpivirine DMJ0QOW Major Increased metabolism of Methadone caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Darunavir DMN3GCH Moderate Decreased metabolism of Methadone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [111]
Verapamil DMA7PEW Moderate Decreased metabolism of Methadone caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [111]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Methadone caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [111]
Conivaptan DM1V329 Moderate Decreased metabolism of Methadone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [111]
Lesinurad DMUR64T Moderate Increased metabolism of Methadone caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [102]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Methadone and Belladonna. Infectious gastroenteritis/colitis [1A40] [131]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Methadone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [111]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Methadone and Suvorexant. Insomnia [7A00-7A0Z] [106]
Amobarbital DM0GQ8N Major Increased metabolism of Methadone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [111]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Methadone and Ramelteon. Insomnia [7A00-7A0Z] [106]
Eszopiclone DM8RZ9H Major Additive CNS depression effects by the combination of Methadone and Eszopiclone. Insomnia [7A00-7A0Z] [106]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Methadone and Flurazepam. Insomnia [7A00-7A0Z] [106]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Methadone and Triazolam. Insomnia [7A00-7A0Z] [106]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Methadone and Zaleplon. Insomnia [7A00-7A0Z] [106]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Methadone and Propiomazine. Insomnia [7A00-7A0Z] [106]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Methadone and Tasimelteon. Insomnia [7A00-7A0Z] [106]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Methadone and Paraldehyde. Insomnia [7A00-7A0Z] [106]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Methadone and ITI-007. Insomnia [7A00-7A0Z] [106]
Zolpidem DMWOSKJ Major Additive CNS depression effects by the combination of Methadone and Zolpidem. Insomnia [7A00-7A0Z] [106]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Methadone and Quazepam. Insomnia [7A00-7A0Z] [106]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Methadone and Estazolam. Insomnia [7A00-7A0Z] [106]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Methadone and Polyethylene glycol. Irritable bowel syndrome [DD91] [137]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Methadone and Phenolphthalein. Irritable bowel syndrome [DD91] [104]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Methadone and Clidinium. Irritable bowel syndrome [DD91] [131]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Methadone and Dicyclomine. Irritable bowel syndrome [DD91] [131]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Methadone and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [106]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Methadone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [107]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Methadone and Crizotinib. Lung cancer [2C25] [138]
Brigatinib DM7W94S Moderate Increased metabolism of Methadone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [102]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Methadone and Ceritinib. Lung cancer [2C25] [104]
PF-06463922 DMKM7EW Major Increased metabolism of Methadone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [102]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Methadone and Osimertinib. Lung cancer [2C25] [104]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Methadone and Selpercatinib. Lung cancer [2C25] [107]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Methadone and Lumefantrine. Malaria [1F40-1F45] [110]
Meprobamate DMHM93Y Major Additive CNS depression effects by the combination of Methadone and Meprobamate. Malaria [1F40-1F45] [106]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Methadone and Halofantrine. Malaria [1F40-1F45] [139]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Methadone and Chloroquine. Malaria [1F40-1F45] [140]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Methadone and Hydroxychloroquine. Malaria [1F40-1F45] [140]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Methadone and Quinine. Malaria [1F40-1F45] [104]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Methadone and Primaquine. Malaria [1F40-1F45] [104]
Mefloquine DMWT905 Major Increased risk of prolong QT interval by the combination of Methadone and Mefloquine. Malaria [1F40-1F45] [104]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Methadone and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [104]
Idelalisib DM602WT Moderate Decreased metabolism of Methadone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
IPI-145 DMWA24P Moderate Decreased metabolism of Methadone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Methadone and Arsenic trioxide. Mature B-cell lymphoma [2A85] [141]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Methadone caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [142]
Arry-162 DM1P6FR Moderate Decreased clearance of Methadone due to the transporter inhibition by Arry-162. Melanoma [2C30] [110]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Methadone and Vemurafenib. Melanoma [2C30] [104]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Methadone and LGX818. Melanoma [2C30] [104]
Dabrafenib DMX6OE3 Major Increased metabolism of Methadone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [102]
Danazol DML8KTN Moderate Decreased metabolism of Methadone caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [111]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Methadone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [143]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Methadone caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [104]
Almogran DM7I64Z Moderate Additive CNS depression effects by the combination of Methadone and Almogran. Migraine [8A80] [100]
Frovatriptan DM7RE8P Moderate Additive serotonergic effects by the combination of Methadone and Frovatriptan. Migraine [8A80] [100]
Rizatriptan DMDJMA3 Moderate Additive serotonergic effects by the combination of Methadone and Rizatriptan. Migraine [8A80] [100]
Naratriptan DMO50U2 Moderate Additive serotonergic effects by the combination of Methadone and Naratriptan. Migraine [8A80] [100]
Sumatriptan DMVYXR8 Moderate Additive serotonergic effects by the combination of Methadone and Sumatriptan. Migraine [8A80] [100]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Methadone and Lasmiditan. Migraine [8A80] [144]
Exjade DMHPRWG Moderate Increased metabolism of Methadone caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [102]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Methadone and Flibanserin. Mood disorder [6A60-6E23] [145]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Methadone and Panobinostat. Multiple myeloma [2A83] [146]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Methadone and Thalidomide. Multiple myeloma [2A83] [147]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Methadone and Siponimod. Multiple sclerosis [8A40] [110]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Methadone and Fingolimod. Multiple sclerosis [8A40] [104]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Methadone and Ozanimod. Multiple sclerosis [8A40] [148]
Carisoprodol DMWR1JC Major Additive CNS depression effects by the combination of Methadone and Carisoprodol. Musculoskeletal disorder [FA00-FC0Z] [106]
Rifabutin DM1YBHK Minor Increased metabolism of Methadone caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [149]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Methadone and Romidepsin. Mycosis fungoides [2B01] [104]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Methadone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [111]
Imatinib DM7RJXL Moderate Decreased metabolism of Methadone caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [111]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Methadone and Dasatinib. Myeloproliferative neoplasm [2A20] [104]
Prasugrel DM7MT6E Moderate Altered absorption of Methadone due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [150]
Modafinil DMYILBE Major Increased metabolism of Methadone caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [102]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Methadone and Droperidol. Nausea/vomiting [MD90] [104]
Prochlorperazine DM53SRA Major Increased risk of prolong QT interval by the combination of Methadone and Prochlorperazine. Nausea/vomiting [MD90] [104]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Methadone and Promethazine. Nausea/vomiting [MD90] [104]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Methadone and Palonosetron. Nausea/vomiting [MD90] [104]
Metoclopramide DMFA5MY Moderate Additive antimotility effects by the combination of Methadone and Metoclopramide. Nausea/vomiting [MD90] [151]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Methadone and Granisetron. Nausea/vomiting [MD90] [104]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Methadone and Dolasetron. Nausea/vomiting [MD90] [104]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Methadone and Ondansetron. Nausea/vomiting [MD90] [104]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Methadone and Bupropion. Nicotine use disorder [6C4A] [152]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Methadone and Entrectinib. Non-small cell lung cancer [2C25] [104]
Sibutramine DMFJTDI Moderate Additive serotonergic effects by the combination of Methadone and Sibutramine. Obesity [5B80-5B81] [100]
Dexfenfluramine DMJ7YDS Moderate Additive CNS depression effects by the combination of Methadone and Dexfenfluramine. Obesity [5B80-5B81] [100]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Methadone and Levomethadyl Acetate. Opioid use disorder [6C43] [107]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Methadone and Lofexidine. Opioid use disorder [6C43] [104]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Methadone and Apraclonidine. Optic nerve disorder [9C40] [134]
Olaparib DM8QB1D Moderate Increased metabolism of Methadone caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [110]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Methadone and Rucaparib. Ovarian cancer [2C73] [104]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Methadone and Pentazocine. Pain [MG30-MG3Z] [153]
Dextropropoxyphene DM23HCX Major Decreased metabolism of Methadone caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [154]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Methadone and Butorphanol. Pain [MG30-MG3Z] [153]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Methadone and Oxymorphone. Pain [MG30-MG3Z] [106]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Methadone and Levorphanol. Pain [MG30-MG3Z] [106]
Dezocine DMJDB0Y Major Additive hypotensive effects by the combination of Methadone and Dezocine. Pain [MG30-MG3Z] [153]
Flavoxate DMKV4NL Moderate Additive CNS depression effects by the combination of Methadone and Flavoxate. Pain [MG30-MG3Z] [108]
Nalbuphine DMOSQGU Major Additive hypotensive effects by the combination of Methadone and Nalbuphine. Pain [MG30-MG3Z] [153]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Methadone and Buprenorphine. Pain [MG30-MG3Z] [104]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Methadone and Hydrocodone. Pain [MG30-MG3Z] [106]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Methadone and Meperidine. Pain [MG30-MG3Z] [106]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Methadone and Oxycodone. Pain [MG30-MG3Z] [106]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Methadone and Triclabendazole. Parasitic worm infestation [1F90] [104]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Methadone and Safinamide. Parkinsonism [8A00] [101]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Methadone and Rasagiline. Parkinsonism [8A00] [101]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Methadone and Biperiden. Parkinsonism [8A00] [128]
Procyclidine DMHFJDT Moderate Additive CNS depression effects by the combination of Methadone and Procyclidine. Parkinsonism [8A00] [128]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Methadone and Pimavanserin. Parkinsonism [8A00] [104]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Methadone and Orphenadrine. Parkinsonism [8A00] [106]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Methadone and Apomorphine. Parkinsonism [8A00] [104]
Abametapir DM2RX0I Moderate Decreased metabolism of Methadone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [155]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Methadone and Lindane. Pediculosis [1G00] [156]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Methadone and Methylscopolamine. Peptic ulcer [DA61] [108]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Methadone and Famotidine. Peptic ulcer [DA61] [110]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Methadone and Macimorelin. Pituitary gland disorder [5A60-5A61] [157]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Methadone and Lefamulin. Pneumonia [CA40] [158]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Methadone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [111]
Ritodrine DM4V6RL Major Increased risk of ventricular arrhythmias by the combination of Methadone and Ritodrine. Preterm labour/delivery [JB00] [116]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Methadone and Degarelix. Prostate cancer [2C82] [104]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Methadone and ABIRATERONE. Prostate cancer [2C82] [104]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Methadone and Nilutamide. Prostate cancer [2C82] [104]
Enzalutamide DMGL19D Major Increased metabolism of Methadone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [102]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Methadone and Flutamide. Prostate cancer [2C82] [104]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Methadone and Relugolix. Prostate cancer [2C82] [104]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Methadone and Bicalutamide. Prostate cancer [2C82] [104]
Alfuzosin DMZVMKF Major Increased risk of prolong QT interval by the combination of Methadone and Alfuzosin. Prostate hyperplasia [GA90] [104]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Methadone due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [107]
Ixekizumab DMXW92T Moderate Altered metabolism of Methadone due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [107]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Methadone and Levomepromazine. Psychotic disorder [6A20-6A25] [104]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Methadone and Triflupromazine. Psychotic disorder [6A20-6A25] [104]
Bosentan DMIOGBU Major Increased metabolism of Methadone caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [102]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Methadone and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [159]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Methadone and Sorafenib. Renal cell carcinoma [2C90] [104]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Methadone and Gatifloxacin. Respiratory infection [CA07-CA4Z] [104]
Tocilizumab DM7J6OR Moderate Altered metabolism of Methadone due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [107]
Canakinumab DM8HLO5 Moderate Altered metabolism of Methadone due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [107]
Rilonacept DMGLUQS Moderate Altered metabolism of Methadone due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [107]
Golimumab DMHZV7X Moderate Altered metabolism of Methadone due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [107]
Dexamethasone DMMWZET Major Increased metabolism of Methadone caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [102]
Nafcillin DMN9RPO Major Increased metabolism of Methadone caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [102]
Sarilumab DMOGNXY Moderate Altered metabolism of Methadone due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [107]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Methadone and Quetiapine. Schizophrenia [6A20] [104]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Methadone and Mesoridazine. Schizophrenia [6A20] [104]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Methadone and Thioridazine. Schizophrenia [6A20] [104]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Methadone and Aripiprazole. Schizophrenia [6A20] [106]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Methadone and Iloperidone. Schizophrenia [6A20] [104]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Methadone and Paliperidone. Schizophrenia [6A20] [104]
Loxapine DM8AI9U Major Additive CNS depression effects by the combination of Methadone and Loxapine. Schizophrenia [6A20] [160]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Methadone and Haloperidol. Schizophrenia [6A20] [104]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Methadone and Perphenazine. Schizophrenia [6A20] [104]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Methadone and Molindone. Schizophrenia [6A20] [106]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Methadone and Chlorpromazine. Schizophrenia [6A20] [104]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Methadone and Thiothixene. Schizophrenia [6A20] [160]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Methadone and Clozapine. Schizophrenia [6A20] [104]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Methadone and Trifluoperazine. Schizophrenia [6A20] [104]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Methadone and Risperidone. Schizophrenia [6A20] [104]
Olanzapine DMPFN6Y Major Additive CNS depression effects by the combination of Methadone and Olanzapine. Schizophrenia [6A20] [160]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Methadone and Amisulpride. Schizophrenia [6A20] [110]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Methadone and Asenapine. Schizophrenia [6A20] [104]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Methadone and Pimozide. Schizophrenia [6A20] [107]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Methadone and Fentanyl. Sensation disturbance [MB40] [106]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Methadone and Vardenafil. Sexual dysfunction [HA00-HA01] [104]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Methadone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [111]
Telotristat ethyl DMDIYFZ Major Increased metabolism of Methadone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [123]
Larotrectinib DM26CQR Moderate Decreased metabolism of Methadone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Armodafinil DMGB035 Major Increased metabolism of Methadone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [102]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Methadone and LEE011. Solid tumour/cancer [2A00-2F9Z] [104]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Methadone and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [104]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Methadone and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [104]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Methadone and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [104]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Methadone and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [104]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Methadone and Pitolisant. Somnolence [MG42] [104]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Methadone and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [104]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Methadone and Adenosine. Supraventricular tachyarrhythmia [BC81] [161]
Fostamatinib DM6AUHV Moderate Decreased clearance of Methadone due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [162]
Brilinta DMBR01X Moderate Decreased metabolism of Methadone caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [111]
Clopidogrel DMOL54H Moderate Altered absorption of Methadone due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [150]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Methadone and Lenvatinib. Thyroid cancer [2D10] [104]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Methadone and Cabozantinib. Thyroid cancer [2D10] [104]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Methadone and Papaverine. Tonus and reflex abnormality [MB47] [163]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Methadone and Tizanidine. Tonus and reflex abnormality [MB47] [106]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Methadone and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [159]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Methadone and Tacrolimus. Transplant rejection [NE84] [104]
Atropine DMEN6X7 Moderate Additive antimotility effects by the combination of Methadone and Atropine. Unspecific substance harmful effect [NE6Z] [131]
Elagolix DMB2C0E Major Increased metabolism of Methadone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [102]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Methadone and Astemizole. Vasomotor/allergic rhinitis [CA08] [104]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Methadone and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [127]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Methadone and Cetirizine. Vasomotor/allergic rhinitis [CA08] [164]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Methadone and Procainamide. Ventricular tachyarrhythmia [BC71] [104]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Methadone and Propafenone. Ventricular tachyarrhythmia [BC71] [104]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Methadone and Flecainide. Ventricular tachyarrhythmia [BC71] [104]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Methadone and Amiodarone. Ventricular tachyarrhythmia [BC71] [104]
⏷ Show the Full List of 368 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrazine yellow E00409 164825 Colorant
Potassium phosphate monobasic E00429 516951 Buffering agent
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Methadone 40 mg tablet 40 mg Tablet for Oral Suspension Oral
Methadone 5 mg tablet 5 mg Oral Tablet Oral
Methadone 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003.
3 BDDCS applied to over 900 drugs
4 Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014 Dec 1;145:185-93. doi: 10.1016/j.drugalcdep.2014.10.014. Epub 2014 Oct 24.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
8 mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
9 In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80(4):304-11.
10 Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
11 Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9.
12 Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
13 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975 Nov 15;2(7942):943-6.
24 Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
25 Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes. Differences from human placental aromatase. J Steroid Biochem. 1988 Jan;29(1):119-25.
26 N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
27 Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev. 2008 Mar;57(2):431-43.
28 Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
29 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
30 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
31 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
32 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
33 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
34 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
35 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
36 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
37 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
38 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
39 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
40 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
41 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
42 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
43 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
44 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
45 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
46 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
47 Drug Interactions Flockhart Table
48 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
49 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
50 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
51 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
52 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
53 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
54 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
55 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
56 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
57 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
58 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
59 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
60 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
61 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
62 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
63 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
64 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
65 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
66 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
67 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
68 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
69 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
70 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
71 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
72 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
73 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
74 Drugs that may have potential CYP2B6 interactions.
75 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
76 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
77 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
78 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
79 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
80 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
81 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
82 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
83 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
84 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
85 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
86 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
87 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
88 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
89 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
90 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
91 The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
92 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
93 Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
94 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
95 Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
96 Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
97 Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
98 Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
99 Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
100 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
101 Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]
102 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
103 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
104 Canadian Pharmacists Association.
105 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
106 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
107 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
108 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
109 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
110 Cerner Multum, Inc. "Australian Product Information.".
111 Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
112 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
113 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
114 Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
115 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
116 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
117 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
118 Ehret GB, Desmeules JA, Broers B "Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology." Expert Opin Drug Saf 6 (2007): 289-303. [PMID: 17480178]
119 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
120 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
121 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
122 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
123 Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM "Rifampin-induced methadone withdrawal." N Engl J Med 294 (1976): 1104-6. [PMID: 1256526]
124 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
125 Abebe-Campino G, Offer D, Stahl B, Merlob P "Cardiac arrhythmia in a newborn infant associated with fluoxetine use during pregnancy." Ann Pharmacother 36 (2002): 533-4. [PMID: 11895072]
126 McCance-Katz EF, Mandell TW "Drug interactions of clinical importance with methadone and buprenorphine." Am J Addict 19 (2010): 2-3. [PMID: 20132116]
127 Gil M, Sala M, Anguera I, et al. "QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone." Am J Cardiol 92 (2003): 995-7. [PMID: 14556883]
128 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
129 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
130 Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
131 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
132 Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM "The effect of fluconazole on the clinical pharmacokinetics of methadone." Clin Pharmacol Ther 63 (1998): 655-62. [PMID: 9663180]
133 De Bels D, Staroukine M, Devriendt J "Torsades de pointes due to methadone." Ann Intern Med 139 (2003): E156. [PMID: 12859181]
134 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
135 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
136 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
137 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
138 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
139 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
140 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
141 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
142 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
143 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
144 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
145 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
146 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
147 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
148 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
149 Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK "Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users." Drug Alcohol Depend 43 (1996): 71-7. [PMID: 8957145]
150 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
151 Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21. [PMID: 3382595]
152 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
153 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
154 Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7. [PMID: 2858217]
155 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
156 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
157 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
158 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
159 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
160 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
161 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
162 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
163 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
164 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.